RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Irinotecan (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms RESILIENT
- Sponsors Ipsen; Merrimack Pharmaceuticals
- 13 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 26 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jun 2017.
- 27 Mar 2017 New trial record